Phase II/III study of SM-88 in patients with metastatic pancreatic ...
2021年1月22日 · Background: SM-88 (racemetyrosine, Tyme Inc) is a dysfunctional tyrosine derivative used with MPS (methoxsalen 10mg, phenytoin 50mg and sirolimus 0.5mg). SM-88 …
总生存期延长一倍！FDA授予创新药物SM-88胰腺癌孤儿药地位
今天，FDA宣布，授予创新药物SM-88（racemetyrosine）授予了 孤儿药 地位，用于治疗胰腺癌患者。 这标志着SM-88是基于癌症代谢的化合物研发中出现的一个重要里程碑！
mTOR靶点的老药和新面孔 |mTOR|雷帕霉素|西罗莫司|新面孔|抑制 …
2021年11月4日 · racemetyrosine (SM-88)是一种新型的联合疗法，包括四种药物，由酪氨酸衍生物（D，L-α-甲基酪氨酸），mTOR抑制剂（西罗莫司），CYP3a4诱导剂（苯妥英）和氧化 …
晚期胰腺癌新药!SM-88治疗显著延长患者生存期 香港港安肿瘤中心特讯：近日宣布，其在研药物组合SM-88…
2019年7月8日 · 香港港安肿瘤中心特讯：近日宣布，其在研药物组合SM-88，作为单药疗法，在治疗晚期胰腺癌患者的开放标签，多中心2期临床试验TYME-88-Panc中，与历史数据相比，显 …
Savoia-Marchetti SM.88 - Wikipedia
The Savoia-Marchetti SM.88, was an Italian twin-engined, three-seat, heavy fighter prototype of World War II, featuring a twin-boom structure, and powered by German Daimler-Benz DB 601 …
SM-88 therapy in patients with advanced or metastatic pancreatic …
2018年2月26日 · Background: SM-88 (tyrosine derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg …
SM-88治疗晚期胰腺癌患者的TYME-88-Panc II期研究：整体生存趋 …
Tyme是一家基于癌症代谢疗法的生物技术公司，近日宣布，评估SM-88（外消旋酪氨酸）单药治疗晚期胰腺癌患者的II期TYME-88-Panc研究表现出令人鼓舞的有效性和安全性。
A first-in-human study of the novel metabolism-based anti ... - PubMed
Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized …
A randomized phase II study of SM-88 plus methoxsalen
Background: This trial explores SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) METHODS: Forty-nine …
Phase II trial of SM-88, a cancer metabolism based therapy, in non ...
Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS) to enhance SM-88 activity. Method A phase 1b/2, open-label trial in BRPC …